{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T05:53:46Z","timestamp":1773726826057,"version":"3.50.1"},"reference-count":51,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2013,3,1]],"date-time":"2013-03-01T00:00:00Z","timestamp":1362096000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of Clinical Orthopaedics and Trauma"],"published-print":{"date-parts":[[2013,3]]},"DOI":"10.1016\/j.jcot.2013.01.010","type":"journal-article","created":{"date-parts":[[2013,2,6]],"date-time":"2013-02-06T05:00:52Z","timestamp":1360126852000},"page":"11-14","source":"Crossref","is-referenced-by-count":1,"title":["We need a break: Bisphosphonates"],"prefix":"10.1016","volume":"4","author":[{"given":"Ashish","family":"Jaiman","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dhananjaya","family":"Sabat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sumit","family":"Arora","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mahmoud A.","family":"Hafez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.jcot.2013.01.010_bib1","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1210\/er.2006-0029","article-title":"Insights into material and structural basis of bone fragility from diseases associated with fractures: how determinants of the biomechanical properties of bone are compromised by disease","volume":"28","author":"Chavassieux","year":"2007","journal-title":"Endocr Rev"},{"issue":"12","key":"10.1016\/j.jcot.2013.01.010_bib2","doi-asserted-by":"crossref","first-page":"3384","DOI":"10.1007\/s11999-010-1535-x","article-title":"Femoral insufficiency fractures associated with prolonged bisphosphonate therapy","volume":"468","author":"Isaacs","year":"2010","journal-title":"Clin Orthop Relat Res"},{"issue":"5","key":"10.1016\/j.jcot.2013.01.010_bib3","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1089\/jwh.2009.1441","article-title":"Long-term effect of the Women's Health Initiative study on antiosteoporosis medication prescribing","volume":"19","author":"Lee","year":"2010","journal-title":"J Womens Health (Larchmt)"},{"key":"10.1016\/j.jcot.2013.01.010_bib4","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1001\/jama.290.13.1729","article-title":"Effects of estrogen plus progestin on risk of fracture and bone mineral density: the Women\u2019s Health Initiative randomized trial","volume":"290","author":"Cauley","year":"2003","journal-title":"JAMA"},{"issue":"14","key":"10.1016\/j.jcot.2013.01.010_bib5","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1001\/jama.291.14.1701","article-title":"Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial","volume":"291","author":"Anderson","year":"2004","journal-title":"JAMA"},{"key":"10.1016\/j.jcot.2013.01.010_bib6","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1056\/NEJMoa030897","article-title":"Ten years' experience with alendronate for osteoporosis in postmenopausal women","volume":"350","author":"Bone","year":"2004","journal-title":"N Engl J Med"},{"issue":"9041","key":"10.1016\/j.jcot.2013.01.010_bib7","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1016\/S0140-6736(96)07088-2","article-title":"Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group","volume":"348","author":"Black","year":"1996","journal-title":"Lancet"},{"issue":"11","key":"10.1016\/j.jcot.2013.01.010_bib8","doi-asserted-by":"crossref","first-page":"4118","DOI":"10.1210\/jc.85.11.4118","article-title":"Fracture risk reduction with alendronate in women with osteoporosis: the Fracture Intervention Trial. FIT Research Group","volume":"85","author":"Black","year":"2000","journal-title":"J Clin Endocrinol Metab"},{"issue":"24","key":"10.1016\/j.jcot.2013.01.010_bib9","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.1001\/jama.280.24.2077","article-title":"Effect of alendronate on risk of fracture in women with low bone\u00a0density but without vertebral fractures: results from the Fracture Intervention Trial","volume":"280","author":"Cummings","year":"1998","journal-title":"JAMA"},{"issue":"22","key":"10.1016\/j.jcot.2013.01.010_bib10","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1056\/NEJM199511303332201","article-title":"Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group","volume":"333","author":"Liberman","year":"1995","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.jcot.2013.01.010_bib11","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1056\/NEJM200102013440503","article-title":"Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group","volume":"344","author":"McClung","year":"2001","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.jcot.2013.01.010_bib12","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1056\/NEJM200008313430902","article-title":"Alendronate for the treatment of osteoporosis in men","volume":"343","author":"Orwoll","year":"2000","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.jcot.2013.01.010_bib13","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1007\/s00198-004-1725-z","article-title":"Meta-analysis of the efficacy of alendronate for the prevention of hip fractures in postmenopausal women","volume":"16","author":"Papapoulos","year":"2005","journal-title":"Osteoporos Int"},{"issue":"5","key":"10.1016\/j.jcot.2013.01.010_bib14","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1007\/PL00004171","article-title":"Multinational, placebo-controlled, randomized trial of the effects of alendronate on bone density and fracture risk in postmenopausal women with low bone mass: results of the FOSIT study. Fosamax International Trial Study Group","volume":"9","author":"Pols","year":"1999","journal-title":"Osteoporos Int"},{"issue":"9","key":"10.1016\/j.jcot.2013.01.010_bib15","doi-asserted-by":"crossref","first-page":"3109","DOI":"10.1210\/jc.85.9.3109","article-title":"Skeletal benefits of alendronate: 7-year treatment of postmenopausal osteoporotic women. Phase III Osteoporosis Treatment Study Group","volume":"85","author":"Tonino","year":"2000","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"10.1016\/j.jcot.2013.01.010_bib16","doi-asserted-by":"crossref","first-page":"367","DOI":"10.5435\/00124635-201006000-00009","article-title":"The orthopaedic implications of diphosphonate therapy","volume":"18","author":"Weaver","year":"2010","journal-title":"J Am Acad Orthop Surg"},{"issue":"5","key":"10.1016\/j.jcot.2013.01.010_bib17","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1016\/S8756-3282(01)00414-8","article-title":"Effects of suppressed bone turnover by bisphosphonates on microdamage accumulation and biomechanical properties in clinically relevant skeletal sites in beagles","volume":"28","author":"Mashiba","year":"2001","journal-title":"Bone"},{"key":"10.1016\/j.jcot.2013.01.010_bib18","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1007\/s002230010036","article-title":"Bisphosphonate treatment suppresses not only stochastic remodeling but also the targeted repair of microdamage","volume":"69","author":"Li","year":"2001","journal-title":"Calcif Tissue Int"},{"key":"10.1016\/j.jcot.2013.01.010_bib19","doi-asserted-by":"crossref","first-page":"2927","DOI":"10.1001\/jama.296.24.2927","article-title":"Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial","volume":"296","author":"Black","year":"2006","journal-title":"JAMA"},{"issue":"6","key":"10.1016\/j.jcot.2013.01.010_bib20","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1097\/01.ogx.0000266070.47052.52","article-title":"Update on the use of bisphosphonates in the management of postmenopausal osteoporosis by obstetricians-gynecologists","volume":"62","author":"Sunyecz","year":"2007","journal-title":"Obstet Gynecol Surv"},{"issue":"2","key":"10.1016\/j.jcot.2013.01.010_bib21","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.injury.2007.08.036","article-title":"An emerging pattern of subtrochanteric stress fractures: a long-term complication of alendronate therapy?","volume":"39","author":"Kwek","year":"2008","journal-title":"Injury"},{"key":"10.1016\/j.jcot.2013.01.010_bib22","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1210\/jc.2004-0952","article-title":"Severely suppressed bone turnover: a potential complication of alendronate therapy","volume":"90","author":"Odvina","year":"2005","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.jcot.2013.01.010_bib23","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1093\/ageing\/afp106","article-title":"Spontaneous femoral shaft fracture after long-term alendronate","volume":"38","author":"Ali","year":"2009","journal-title":"Age Ageing"},{"issue":"7","key":"10.1016\/j.jcot.2013.01.010_bib24","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/S0025-6196(11)60752-0","article-title":"Adverse effects of bisphosphonates: implications for osteoporosis management","volume":"84","author":"Kennel","year":"2009","journal-title":"Mayo Clin Proc"},{"issue":"11","key":"10.1016\/j.jcot.2013.01.010_bib25","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1517\/17425255.4.11.1371","article-title":"Skeletal accumulation of bisphosphonates: implications for osteoporosis treatment","volume":"4","author":"Allen","year":"2008","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"4","key":"10.1016\/j.jcot.2013.01.010_bib26","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1359\/jbmr.1998.13.4.581","article-title":"Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras","volume":"13","author":"Luckman","year":"1998","journal-title":"J Bone Miner Res"},{"issue":"6","key":"10.1016\/j.jcot.2013.01.010_bib27","doi-asserted-by":"crossref","first-page":"317","DOI":"10.5435\/00124635-201006000-00003","article-title":"Guest editorial the implications of prolonged diphosphonate therapy","volume":"18","author":"Frassica","year":"2010","journal-title":"J Am Acad Orthop Surg"},{"issue":"7","key":"10.1016\/j.jcot.2013.01.010_bib28","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1038\/nm.1979","article-title":"TGF-beta1-induced migration of bone mesenchymal stem cells couples bone resorption with formation","volume":"15","author":"Tang","year":"2009","journal-title":"Nat Med"},{"issue":"8","key":"10.1016\/j.jcot.2013.01.010_bib29","doi-asserted-by":"crossref","first-page":"2948","DOI":"10.1210\/jc.2007-2803","article-title":"Severely suppressed bone turnover and atypical skeletal fragility","volume":"93","author":"Visekruna","year":"2008","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"10.1016\/j.jcot.2013.01.010_bib30","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1302\/0301-620X.89B3.18146","article-title":"Subtrochanteric insufficiency fractures in patients on alendronate therapy: a caution","volume":"89","author":"Goh","year":"2007","journal-title":"J Bone Joint Surg Br"},{"issue":"1","key":"10.1016\/j.jcot.2013.01.010_bib31","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.maturitas.2009.11.002","article-title":"Bisphosphonates and atypical femoral fractures: a time for reflection","volume":"65","author":"Compston","year":"2010","journal-title":"Maturitas"},{"issue":"12","key":"10.1016\/j.jcot.2013.01.010_bib32","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1056\/NEJMc0707493","article-title":"Atypical fractures of the femoral diaphysis in postmenopausal women taking alendronate","volume":"358","author":"Lenart","year":"2008","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.jcot.2013.01.010_bib33","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1007\/s00198-008-0805-x","article-title":"Association of low-energy femoral fractures with prolonged bisphosphonate use: a case control study","volume":"20","author":"Lenart","year":"2009","journal-title":"Osteoporos Int"},{"issue":"6","key":"10.1016\/j.jcot.2013.01.010_bib34","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1359\/jbmr.2003.18.6.1012","article-title":"Aging of microstructural compartments in human compact bone","volume":"18","author":"Akkus","year":"2003","journal-title":"J Bone Miner Res"},{"issue":"9","key":"10.1016\/j.jcot.2013.01.010_bib35","doi-asserted-by":"crossref","first-page":"775","DOI":"10.2165\/00002018-200932090-00002","article-title":"Low-energy femoral fractures associated with the long-term use of bisphosphonates: a case series from a Swiss university hospital","volume":"32","author":"Ing-Lorenzini","year":"2009","journal-title":"Drug Saf"},{"issue":"4","key":"10.1016\/j.jcot.2013.01.010_bib36","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/S0090-9556(25)08706-9","article-title":"Effects of dose, sex, and age on the disposition of alendronate, a potent antiosteolytic bisphosphonate, in rats","volume":"20","author":"Lin","year":"1992","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.jcot.2013.01.010_bib37","doi-asserted-by":"crossref","first-page":"27","DOI":"10.2147\/ORR.S7521","article-title":"Bisphosphonate-induced femoral fragility fractures: what do we know?","volume":"2","author":"Sayed-Noor","year":"2010","journal-title":"Orthop Res Rev"},{"key":"10.1016\/j.jcot.2013.01.010_bib38","doi-asserted-by":"crossref","DOI":"10.1136\/bcr.10.2008.1073","article-title":"Atypical femoral diaphyseal and subtrochanteric fractures and their association with bisphosphonates","author":"Leung","year":"2009","journal-title":"BMJ Case Rep"},{"issue":"4","key":"10.1016\/j.jcot.2013.01.010_bib39","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1080\/13697130801959590","article-title":"Potential excessive suppression of bone turnover with long-term oral bisphosphonate therapy in postmenopausal osteoporotic patients","volume":"11","author":"Iizuka","year":"2008","journal-title":"Climacteric"},{"issue":"12","key":"10.1016\/j.jcot.2013.01.010_bib40","doi-asserted-by":"crossref","first-page":"994","DOI":"10.2146\/ajhp090506","article-title":"Risks and benefits of long-term bisphosphonate therapy","volume":"67","author":"Schmidt","year":"2010","journal-title":"Am J Health Syst Pharm"},{"issue":"1","key":"10.1016\/j.jcot.2013.01.010_bib41","first-page":"18","article-title":"Bisphosphonates and low-impact femoral fractures: current evidence on alendronate-fracture risk","volume":"64","author":"Schneider","year":"2009","journal-title":"Geriatrics"},{"key":"10.1016\/j.jcot.2013.01.010_bib42","unstructured":"NHS \u2013 National Institute for health and clinical excellence; NICE technology appraisal guidance 160 (amended January 2010). Alendronate, etidronate, risedronate, raloxifene and strontium ranelate for the primary prevention of osteoporotic fragility fractures in postmenopausal women (amended)."},{"key":"10.1016\/j.jcot.2013.01.010_bib43","unstructured":"NHS \u2013 National Institute for health and clinical excellence; NICE technology appraisal guidance 161 (amended January 2010). Alendronate, etidronate, risedronate, raloxifene, strontium ranelate and teriparatide for the secondary prevention of osteoporotic fragility fractures in postmenopausal women (amended)."},{"issue":"11","key":"10.1016\/j.jcot.2013.01.010_bib44","doi-asserted-by":"crossref","first-page":"2556","DOI":"10.2106\/JBJS.H.01774","article-title":"Bilateral low-energy simultaneous or sequential femoral fractures in patients on long-term alendronate therapy","volume":"91","author":"Capeci","year":"2009","journal-title":"J Bone Joint Surg Am"},{"issue":"4","key":"10.1016\/j.jcot.2013.01.010_bib45","doi-asserted-by":"crossref","first-page":"995","DOI":"10.2214\/AJR.07.3714","article-title":"MRI and CT of insufficiency fractures of the pelvis and the proximal femur","volume":"191","author":"Cabarrus","year":"2008","journal-title":"Am J Roentgenol"},{"issue":"4","key":"10.1016\/j.jcot.2013.01.010_bib46","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1016\/j.bone.2010.01.377","article-title":"Postoperative use of bisphosphonates and risk of revision after primary total hip arthroplasty: a nationwide population-based study","volume":"46","author":"Thillemann","year":"2010","journal-title":"Bone"},{"issue":"2","key":"10.1016\/j.jcot.2013.01.010_bib47","doi-asserted-by":"crossref","first-page":"274","DOI":"10.2106\/JBJS.G.01193","article-title":"The effect of a single infusion of zoledronic acid on early implant migration in total hip arthroplasty. A randomized, double-blind, controlled trial","volume":"91","author":"Friedl","year":"2009","journal-title":"J Bone Joint Surg Am"},{"issue":"5","key":"10.1016\/j.jcot.2013.01.010_bib48","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1016\/j.semarthrit.2010.06.010","article-title":"Statins and the joint: multiple targets for a global protection?","volume":"40","author":"Lazzerini","year":"2011","journal-title":"Semin Arthritis Rheum"},{"issue":"2","key":"10.1016\/j.jcot.2013.01.010_bib49","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1007\/s00198-008-0650-y","article-title":"Vitamin D status and response to treatment in post-menopausal osteoporosis","volume":"20","author":"Adami","year":"2009","journal-title":"Osteoporos Int"},{"issue":"3","key":"10.1016\/j.jcot.2013.01.010_bib50","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1210\/jc.2005-0057","article-title":"Long-term safety of bisphosphonates","volume":"90","author":"Ott","year":"2005","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"10.1016\/j.jcot.2013.01.010_bib51","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1097\/MED.0b013e328317ca83","article-title":"Osteoporosis: how long should we treat?","volume":"15","author":"Sebba","year":"2008","journal-title":"Curr Opin Endocrinol Diabetes Obes"}],"container-title":["Journal of Clinical Orthopaedics and Trauma"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0976566213000118?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0976566213000118?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,4,29]],"date-time":"2025-04-29T19:57:33Z","timestamp":1745956653000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0976566213000118"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,3]]},"references-count":51,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2013,3]]}},"alternative-id":["S0976566213000118"],"URL":"https:\/\/doi.org\/10.1016\/j.jcot.2013.01.010","relation":{},"ISSN":["0976-5662"],"issn-type":[{"value":"0976-5662","type":"print"}],"subject":[],"published":{"date-parts":[[2013,3]]}}}